Christine Kirlew
Internal Medicine · New Port Richey, FLNPI 1851657399
Payments from drug & device makers
Across 147 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$271
- Pfizer$232
- Abbott$188
- Novo Nordisk$149
- Merck$142
- Johnson & Johnson$142
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,43999%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $271 |
| Pfizer | 13 | $232 |
| Abbott | 14 | $188 |
| Novo Nordisk | 8 | $149 |
| Merck | 9 | $142 |
| Johnson & Johnson | 11 | $142 |
| Paratek Pharmaceuticals, Inc. | 6 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $130 |
| Exact Sciences | 9 | $129 |
| AstraZeneca | 7 | $112 |
| Amgen | 6 | $108 |
| Boehringer Ingelheim | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Biohaven Pharmaceuticals, Inc. | 5 | $83 |
| GSK | 4 | $71 |
| AbbVie | 4 | $62 |
| Eisai Inc. | 3 | $49 |
| Medtronic | 1 | $46 |
| Gilead | 3 | $43 |
| Radius Health, Inc. | 3 | $40 |
| Bayer | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $12 |
| Dermira, Inc. | 1 | $11 |
How this compares
$2,453 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $10,796 |
| OzempicSemaglutide | 11 | $8,890 |
| Atorvastatin Calcium | 90 | $769 |
| Levothyroxine Sodium | 56 | $755 |
| Gabapentin | 18 | $682 |
| SynthroidLevothyroxine Sodium | 11 | $545 |
| Metoprolol Succinate | 39 | $534 |
| Rosuvastatin Calcium | 61 | $511 |
| Potassium Chloride | 12 | $498 |
| Losartan Potassium | 29 | $460 |
| Lisinopril | 74 | $410 |
| Carbamazepine | 17 | $370 |
| Sertraline Hcl | 49 | $365 |
| Omeprazole | 30 | $343 |
| Simvastatin | 45 | $310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $232 | $10,79617 claims |
| Novo NordiskOzempic | $149 | $8,89011 claims |
| AbbVieSynthroid | $62 | $54511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in New Port Richey
- Richard PowellNew Port Richey$8.1M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.